Introduction: The Oral Delivery Challenge
The overwhelming majority of peptide-based therapeutics — including insulin, growth hormone, and GLP-1 receptor agonists — are administered by injection. This is not a limitation of drug design preference; it reflects the fundamental hostility of the gastrointestinal tract toward peptide molecules. Stomach acid denatures tertiary structure, pepsin and pancreatic proteases cleave peptide bonds, and the intestinal epithelium presents a formidable barrier to the absorption of large, hydrophilic molecules. The result is that most orally ingested peptides are destroyed before reaching systemic circulation, with bioavailability approaching zero.[1][2]
The development of orally bioavailable GLP-1 receptor agonists has followed two fundamentally different strategies. The first — exemplified by oral GLP-1 agonist peptide (Rybelsus) — uses an absorption enhancer to force a peptide through the gastric epithelium despite its inherent unsuitability for oral delivery. The second — exemplified by orforglipron (Eli Lilly) — abandons the peptide scaffold entirely, replacing it with a small non-peptide molecule that achieves oral bioavailability through conventional pharmaceutical absorption mechanisms. These two approaches represent distinct philosophies with different trade-offs in efficacy, convenience, manufacturability, and cost. For foundational GLP-1 receptor biology underlying both approaches, see our GLP-1 receptor agonists science guide.
The Injectable Standard: Why Subcutaneous Delivery Works
Subcutaneous injection bypasses every barrier that makes oral peptide delivery difficult. The peptide enters the interstitial fluid intact, is absorbed into local capillaries or lymphatics, and reaches systemic circulation with near-complete bioavailability. For GLP-1 receptor agonists like injectable GLP-1 agonist peptide and GLP dual agonist peptide, fatty acid acylation enables albumin binding that extends the circulating half-life to approximately one week, permitting once-weekly dosing from a single subcutaneous injection.[1]
The disadvantage is patient acceptance. Injection aversion is a well-documented barrier to treatment initiation, particularly in primary care settings where obesity and early type 2 diabetes are most commonly managed. Survey data consistently show that many patients prefer oral medications, and some decline injectable therapies entirely despite clinical benefit. This preference gap has driven intense commercial and scientific interest in oral GLP-1 formulations — not because injections are pharmacologically inferior, but because an effective oral option could dramatically expand the treatable population.
Oral GLP-1 agonist peptide: The SNAC Absorption Enhancer Approach
SNAC Mechanism of Action
Oral GLP-1 agonist peptide (Rybelsus, Novo Nordisk) was the first oral GLP-1 receptor agonist, approved by the FDA in 2019. It uses the same GLP-1 agonist peptide peptide molecule as the injectable formulation, co-formulated with 300 mg of SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) in each tablet. SNAC is a synthetic fatty acid derivative originally developed by Emisphere Technologies as part of their Eligen platform and first used commercially for oral vitamin B12 delivery. It carries FDA GRAS (Generally Recognized As Safe) designation.[2][3]
The mechanism by which SNAC enables gastric peptide absorption involves three coordinated actions. First, as the tablet erodes in the stomach, SNAC creates a localized pH increase through buffering that protects GLP-1 agonist peptide from pepsin-mediated degradation — pepsinogen conversion to active pepsin is pH-dependent, and the local alkalinization suppresses proteolytic activity in the immediate vicinity of the dissolving tablet. Second, SNAC promotes monomerization of GLP-1 agonist peptide by altering the local polarity environment, disrupting the hydrophobic interactions that would otherwise cause GLP-1 agonist peptide to aggregate into oligomers too large for absorption. Third, SNAC embeds into the lipid membranes of gastric epithelial cells and transiently fluidizes them, creating a window of increased transcellular permeability that allows monomerized GLP-1 agonist peptide to cross the gastric wall into the lamina propria and local capillaries.[2][3]
Critically, scintigraphic imaging in human volunteers and pyloric ligation studies in dogs have confirmed that absorption occurs in the stomach, not the intestine — a departure from the absorption site of virtually all other oral drugs. Plasma GLP-1 agonist peptide concentrations in splenic vein drainage (from the stomach) were significantly higher than in portal vein drainage (from the intestinal tract), confirming gastric absorption. The SNAC effect is transient and fully reversible, with no evidence of tight junction disruption — it operates exclusively through the transcellular route.[3]
The Bioavailability Gap
Despite this elegant mechanism, the fundamental limitation of oral GLP-1 agonist peptide is bioavailability: approximately 0.8% of the ingested dose reaches systemic circulation, compared to near-complete absorption with subcutaneous injection. This means that to achieve equivalent therapeutic exposure, the oral dose must be roughly 100-fold higher than the injectable dose. The approved oral GLP-1 agonist peptide doses for type 2 diabetes are 7 mg and 14 mg daily (versus 0.5-2 mg weekly by injection), while higher doses of 25 mg and 50 mg daily are under investigation in the OASIS trial program for obesity and enhanced glycemic control.[2][3]
This low bioavailability creates strict dosing requirements that are central to the clinical experience with oral GLP-1 agonist peptide: the tablet must be taken on an empty stomach, swallowed with no more than 120 mL (4 oz) of plain water, and no food, other beverages, or other oral medications should be consumed for at least 30 minutes afterward. These restrictions exist because food, excessive fluid volume, and concurrent medications all interfere with the precisely choreographed SNAC-GLP-1 agonist peptide absorption process in the stomach. Non-compliance with these conditions can substantially reduce absorption and therapeutic efficacy.[2]
Despite the once-weekly half-life of GLP-1 agonist peptide itself, oral GLP-1 agonist peptide requires daily dosing. This is because the highly variable day-to-day absorption (coefficient of variation approximately 80-120%) necessitates daily dosing to maintain consistent steady-state plasma levels — the pharmacokinetic variability from a single oral dose is too great to sustain therapeutic concentrations over an entire week.
Clinical Efficacy of Oral GLP-1 agonist peptide
The PIONEER clinical trial program established oral GLP-1 agonist peptide 14 mg as effective for glycemic control in type 2 diabetes, with HbA1c reductions and modest weight loss comparable to other GLP-1 RA classes, though generally less than the higher injectable GLP-1 agonist peptide doses. The PIONEER PLUS trial evaluated higher oral GLP-1 agonist peptide doses (25 mg and 50 mg daily), demonstrating enhanced glycemic and weight loss efficacy that begins to approach injectable GLP-1 agonist peptide results. The OASIS program is further exploring these higher doses for obesity indications.[1]
The Small-Molecule Revolution: Orforglipron
From Peptide to Non-Peptide
Orforglipron (LY3502970, Eli Lilly) represents a fundamentally different approach to oral GLP-1 agonism. Rather than attempting to deliver a peptide through a hostile gastrointestinal environment using absorption enhancers, orforglipron is a non-peptide, small-molecule compound that activates the GLP-1 receptor through a different binding mode than native GLP-1. It was discovered by Chugai Pharmaceutical and licensed by Lilly in 2018. As a small molecule, it is absorbed through conventional gastrointestinal mechanisms — no absorption enhancer is required, and there are no restrictions on food or water intake. It can be taken at any time of day.[4][5]
The structural basis for orforglipron's activity was elucidated through cryo-electron microscopy, revealing that the small molecule binds within the transmembrane domain of the GLP-1 receptor — a distinct binding site from the peptide ligands that engage the receptor's extracellular domain and transmembrane core. This different binding mode activates the same Gs-cAMP signaling cascade but may produce subtly different receptor conformations and downstream signaling kinetics compared to peptide agonists.[5]
Phase 3 Clinical Evidence
Orforglipron has completed multiple Phase 3 trials with consistently positive results. In the ACHIEVE-1 trial (type 2 diabetes, diet/exercise only), orforglipron at 3, 12, and 36 mg once daily significantly reduced HbA1c compared to placebo over 40 weeks. The ACHIEVE-1 results, published in the New England Journal of Medicine in 2025, established orforglipron as the first oral non-peptide GLP-1 RA to successfully complete a Phase 3 trial.[5]
In the ATTAIN-1 trial (obesity without type 2 diabetes), orforglipron 36 mg produced an average weight loss of 12.4% at 72 weeks (treatment-regimen estimand) and 11.2% (efficacy estimand), with 54.6% of patients achieving at least 10% weight loss and 36.0% achieving at least 15%. Weight loss was dose-dependent across the 6, 12, and 36 mg dose groups. Significant improvements in waist circumference, systolic blood pressure, triglycerides, and non-HDL cholesterol were observed across all doses. Among the 1,127 participants with prediabetes at baseline, up to 91% of those receiving orforglipron achieved near-normal blood sugar levels compared to 42% on placebo.[4][6]
In the ATTAIN-2 trial (obesity with type 2 diabetes), orforglipron 36 mg reduced body weight by 10.5% at 72 weeks (efficacy estimand, vs 2.2% placebo) and HbA1c by up to 1.66%. These results exceed what is typically achieved with existing oral diabetes medications in this population and approach the efficacy of injectable GLP-1 receptor agonists.[7]
Weight Maintenance: ATTAIN-Maintain
A particularly noteworthy finding comes from the ATTAIN-Maintain trial (2025), which evaluated whether patients could transition from injectable therapy (GLP-1 agonist peptide or GLP dual agonist peptide) to oral orforglipron for long-term weight maintenance. Participants from the comparative trial trial who had reached a body weight plateau on injectable therapy were re-randomized to orforglipron or placebo for 52 weeks. Patients who switched from (GLP-1 agonist peptide) to orforglipron maintained their previously achieved weight loss with an average difference of only 2 pounds. Those switching from Zepbound (GLP dual agonist peptide) to orforglipron maintained their weight loss with an average difference of 11 pounds. In contrast, placebo groups experienced substantial weight regain — approximately 20.7 pounds for former users and comparable regain for former Zepbound users at 24 weeks.[8]
This trial has significant implications for the clinical management of obesity as a chronic disease: it suggests that patients could potentially initiate aggressive weight loss with an injectable incretin and then transition to a more convenient oral agent for long-term maintenance, rather than continuing injections indefinitely.
Comparing the Three Approaches
Efficacy
Injectable GLP-1 agonists currently produce the greatest weight loss: GLP-1 agonist peptide 2.4 mg achieves approximately 15% at 68-72 weeks, and GLP dual agonist peptide 15 mg achieves approximately 20-22%. Oral GLP-1 agonist peptide at approved doses (7-14 mg) produces more modest results, though higher doses (25-50 mg) in the OASIS program approach injectable efficacy. Orforglipron 36 mg achieves approximately 12.4% weight loss in adults with obesity — meaningful but still below injectable GLP-1 agonist peptide and substantially below GLP dual agonist peptide. The efficacy gap between oral and injectable formulations may narrow as oral agents are optimized and higher doses are explored.[4][6]
Convenience and Adherence
Oral GLP-1 agonist peptide requires daily dosing with strict fasting conditions (empty stomach, minimal water, 30-minute wait). Orforglipron requires daily dosing but without any food or water restrictions — it can be taken any time of day with or without meals. Injectable GLP-1 agonist peptide and GLP dual agonist peptide require once-weekly subcutaneous injection using prefilled pen devices. The convenience hierarchy depends on patient preferences: some prefer the simplicity of a daily pill (especially without restrictions), others prefer a once-weekly injection over daily dosing, and some are motivated primarily by maximizing efficacy regardless of route.
Manufacturing and Cost Implications
Small-molecule oral agents like orforglipron may offer significant advantages in manufacturing scalability and cost. Peptide synthesis — whether for injectable or oral peptide formulations — requires specialized manufacturing infrastructure (solid-phase peptide synthesis, purification, quality control for large molecules). Small-molecule synthesis uses conventional pharmaceutical chemistry with well-established scale-up pathways. Eli Lilly has stated confidence in its ability to launch orforglipron worldwide without supply constraints — a notable contrast to the persistent supply shortages that have affected injectable GLP-1 agonist peptide and GLP dual agonist peptide since their launch. This scalability could ultimately improve global access to effective incretin-based therapy.[5]
Implications for Peptide Research
The oral GLP-1 landscape illustrates a broader tension in peptide therapeutics: the trade-off between the exquisite receptor selectivity of peptide ligands and the practical advantages of small-molecule drugs. Peptides like GLP-1 agonist peptide and GLP dual agonist peptide can be engineered with precise receptor pharmacology — biased agonism, multi-receptor selectivity, tunable half-lives through lipidation — but they face inherent delivery challenges. Small molecules offer superior oral bioavailability but may lack the pharmacological precision of peptide ligands. For researchers working with research peptides, this tension is relevant across many therapeutic areas beyond GLP-1.
The success of SNAC-based oral GLP-1 agonist peptide has implications for other peptide delivery systems. The principle that localized pH buffering, monomerization, and transient membrane fluidization can achieve transcellular peptide absorption in the stomach is being explored for other peptide therapeutics. However, the low bioavailability (less than 1%) and strict dosing requirements remain significant limitations that small-molecule approaches avoid entirely. For a deeper understanding of peptide stability and the factors that affect it — including pH sensitivity, aggregation, and enzymatic degradation — see our peptide stability research guide and our article on lyophilized peptides.
The Evolving Pipeline
The oral GLP-1 space is expanding rapidly beyond GLP-1 agonist peptide and orforglipron. Danuglipron (Pfizer) is another non-peptide small-molecule GLP-1 RA that has undergone clinical development, though with a twice-daily dosing regimen and a GI tolerability profile that has presented challenges in clinical trials. Oral dual and triple agonists are in earlier stages of development, aiming to replicate the multi-receptor pharmacology of injectable agents like GLP dual agonist peptide in oral form. The concept of oral multi-agonism — combining GLP-1, GIP, and/or glucagon receptor activity in a single oral molecule — remains technically challenging but is an active area of medicinal chemistry research.
For context on the multi-receptor agonist landscape that oral agents will need to match, see our articles on injectable agents including NA-931 (Bioglutide) and the broader discussion of GLP-1 effects beyond weight loss.
Summary
The oral versus injectable GLP-1 agonist comparison spans two distinct technological generations. Oral GLP-1 agonist peptide (Rybelsus) proved that oral peptide GLP-1 delivery is possible using SNAC absorption enhancement, but at the cost of less than 1% bioavailability, strict fasting requirements, and daily dosing. Orforglipron has demonstrated that non-peptide small molecules can activate the GLP-1 receptor with sufficient potency to produce clinically meaningful weight loss (12.4% at 72 weeks) and glycemic control, without food restrictions or special formulation requirements, and with manufacturing advantages that could improve global supply. Injectable agents retain the efficacy advantage — particularly GLP dual agonist peptide's dual GIP/GLP-1 agonism delivering 20%+ weight loss — but oral options are narrowing the gap and may transform treatment paradigms through improved accessibility and the possibility of injectable-to-oral treatment sequencing for chronic weight management.
